Jesus M Banales

List of Publications by Citations

163 papers	6,161 citations	43 h-index	74 g-index
185 ext. papers	8,508 ext. citations	8.4 avg, IF	5.69 L-index

#	Paper	IF	Citations
163	Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). *Nature Reviews Gastroenterology and Hepatology*, **2016**, 13, 261-80	24.2	618
162	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. *Nature Reviews Gastroenterology and Hepatology*, **2020**, 17, 557-588	24.2	355
161	Mutations in GANAB, Encoding the Glucosidase IIβ Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. *American Journal of Human Genetics*, **2016**, 98, 1193-1207	11	240
160	Biliary exosomes influence cholangiocyte regulatory mechanisms and proliferation through interaction with primary cilia. *American Journal of Physiology - Renal Physiology*, **2010**, 299, G990-9	5.1	187
159	Cholangiocyte cilia express TRPV4 and detect changes in luminal tonicity inducing bicarbonate secretion. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 19138-43	11.5	164
158	Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. *Hepatology*, **2012**, 56, 687-97	11.2	160
157	Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. *Gastroenterology*, **2008**, 134, 1482-93	13.3	159
156	Wnt-β-catenin signalling in liver development, health and disease. *Nature Reviews Gastroenterology and Hepatology*, **2019**, 16, 121-136	24.2	156
155	Cholangiocyte pathobiology. *Nature Reviews Gastroenterology and Hepatology*, **2019**, 16, 269-281	24.2	155
154	Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. *Hepatology*, **2017**, 66, 1125-1143	11.2	148
153	MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. *Journal of Clinical Investigation*, **2008**, 118, 3714-24	15.9	133
152	Cholangiocyte primary cilia are chemosensory organelles that detect biliary nucleotides via P2Y12 purinergic receptors. *American Journal of Physiology - Renal Physiology*, **2008**, 295, G725-34	5.1	125
151	Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. *Hepatology*, **2013**, 58, 1065-73	11.2	102
150	Cholangiocyte anion exchange and biliary bicarbonate excretion. *World Journal of Gastroenterology*, **2006**, 12, 3496-511	5.6	96
149	The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). *Hepatology*, **2009**, 49, 160-74	11.2	95
148	Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. *Journal of Hepatology*, **2017**, 66, 102-115	13.4	91
147	Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma. *Journal of Hepatology*, **2017**, 67, 282-292	13.4	85

146	Bile Acids in Physiology, Pathology and Pharmacology. *Current Drug Metabolism*, **2015**, 17, 4-29	3.5	83
145	Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger. *Hepatology*, **2006**, 43, 266-75	11.2	79
144	Methods for extracellular vesicles isolation in a hospital setting. *Frontiers in Immunology*, **2015**, 6, 50	8.4	75
143	Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. *Hepatology*, **2013**, 58, 409-21	11.2	74
142	Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease. *Journal of Crohn's and Colitis*, **2017**, 11, 1430-1439	1.5	72
141	Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD. *Gastroenterology*, **2010**, 139, 304-14.e2	13.3	72
140	miRNA-21 ablation protects against liver injury and necroptosis in cholestasis. *Cell Death and Differentiation*, **2018**, 25, 857-872	12.7	71
139	Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. *Hepatology Communications*, **2018**, 2, 807-820	6	64
138	Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. *Gut*, **2016**, 65, 1535-45	19.2	62
137	Polycystic liver diseases: advanced insights into the molecular mechanisms. *Nature Reviews Gastroenterology and Hepatology*, **2014**, 11, 750-61	24.2	61
136	Clinical management of polycystic liver disease. *Journal of Hepatology*, **2018**, 68, 827-837	13.4	60
135	Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. *American Journal of Pathology*, **2008**, 173, 1637-46	5.8	58
134	SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. *Journal of Hepatology*, **2017**, 67, 72-83	13.4	57
133	Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. *Hepatology*, **2019**, 69, 587-603	11.2	56
132	Metabolic rearrangements in primary liver cancers: cause and consequences. *Nature Reviews Gastroenterology and Hepatology*, **2019**, 16, 748-766	24.2	54
131	Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. *Hepatology*, **2019**, 70, 547-562	11.2	54
130	Diagnostic and prognostic biomarkers in cholangiocarcinoma. *Liver International*, **2019**, 39 Suppl 1, 108-122	7.9	53
129	Post-translational regulation of the type III inositol 1,4,5-trisphosphate receptor by miRNA-506. *Journal of Biological Chemistry*, **2015**, 290, 184-96	5.4	51

128	Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development. *Molecular Cancer Research*, **2014**, 12, 91-100	6.6	50
127	The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2018**, 1864, 1468-1477	6.9	49
126	Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 216-225.e5	6.9	46
125	The challenges of primary biliary cholangitis: What is new and what needs to be done. *Journal of Autoimmunity*, **2019**, 105, 102328	15.5	45
124	MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation. *Hepatology*, **2018**, 67, 1420-1440	11.2	45
123	Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. *Journal of Hepatology*, **2015**, 63, 952-61	13.4	44
122	PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery. *Surgery for Obesity and Related Diseases*, **2016**, 12, 1838-1846	3	44
121	The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 1260-1270	6.1	43
120	Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. *Gut*, **2014**, 63, 1658-67	19.2	42
119	Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2018**, 1864, 1335-1344	6.9	39
118	Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases. *Nature Reviews Gastroenterology and Hepatology*, **2019**, 16, 497-511	24.2	38
117	MicroRNA (miR)-433 and miR-22 dysregulations induce histone-deacetylase-6 overexpression and ciliary loss in cholangiocarcinoma. *Hepatology*, **2018**, 68, 561-573	11.2	37
116	Matrix metalloproteinase-10 expression is induced during hepatic injury and plays a fundamental role in liver tissue repair. *Liver International*, **2014**, 34, e257-70	7.9	37
115	Shared apical sorting of anion exchanger isoforms AE2a, AE2b1, and AE2b2 in primary hepatocytes. *Biochemical and Biophysical Research Communications*, **2004**, 319, 1040-6	3.4	36
114	Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis. *Cells*, **2020**, 9,	7.9	34
113	Bicarbonate secretion of mouse cholangiocytes involves Na(+)-HCO(3)(-) cotransport in addition to Na(+)-independent Cl(-)/HCO(3)(-) exchange. *Hepatology*, **2010**, 51, 891-902	11.2	33
112	Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids. *Cell Stem Cell*, **2021**, 28, 816-832	18	32
111	Type 3 Inositol 1,4,5-Trisphosphate Receptor Is Increased and Enhances Malignant Properties in Cholangiocarcinoma. *Hepatology*, **2020**, 71, 583-599	11.2	32

110	Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease. *Gastroenterology*, **2012**, 142, 622-633.e4	13.3	31
109	Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy. *Hepatology*, **2019**, 70, 1246-1261	11.2	30
108	Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib. *British Journal of Pharmacology*, **2019**, 176, 787-800	8.6	30
107	MicroRNAs and cholestatic liver diseases. *Current Opinion in Gastroenterology*, **2014**, 30, 303-9	3	28
106	Ursodeoxycholic acid is conjugated with taurine to promote secretin-stimulated biliary hydrocholeresis in the normal rat. *PLoS ONE*, **2011**, 6, e28717	3.7	28
105	MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis. *Cell Death and Disease*, **2018**, 9, 958	9.8	28
104	Elevated interleukin-8 in bile of patients with primary sclerosing cholangitis. *Liver International*, **2016**, 36, 1370-7	7.9	27
103	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. *Journal of Hepatology*, **2020**, 73, 17-25	13.4	26
102	Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial. *Journal of Hepatology*, **2016**, 65, 601-7	13.4	26
101	Histone deacetylase 4 promotes cholestatic liver injury in the absence of prohibitin-1. *Hepatology*, **2015**, 62, 1237-48	11.2	25
100	Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study. *Journal of Crohn's and Colitis*, **2019**, 13, 1492-1500	1.5	24
99	Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT). *Journal of Controlled Release*, **2015**, 216, 93-102	11.7	24
98	MicroRNAs in biliary diseases. *World Journal of Gastroenterology*, **2012**, 18, 6189-96	5.6	24
97	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. *Journal of Hepatology*, **2021**, 74, 20-30	13.4	24
96	Nlrp3 Activation Induces Il-18 Synthesis and Affects the Epithelial Barrier Function in Reactive Cholangiocytes. *American Journal of Pathology*, **2017**, 187, 366-376	5.8	23
95	Lignins from Agroindustrial by-Products as Natural Ingredients for Cosmetics: Chemical Structure and In Vitro Sunscreen and Cytotoxic Activities. *Molecules*, **2020**, 25,	4.8	23
94	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. *British Journal of Cancer*, **2020**, 123, 1047-1059	8.7	23
93	Extracellular Vesicles in NAFLD/ALD: From Pathobiology to Therapy. *Cells*, **2020**, 9,	7.9	22

92	Anion exchanger 2 is critical for CD8(+) T cells to maintain pHi homeostasis and modulate immune responses. *European Journal of Immunology*, **2014**, 44, 1341-51	6.1	22
91	Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part I: Classification, diagnosis and staging. *Digestive and Liver Disease*, **2020**, 52, 1282-1293	3.3	21
90	Fine-Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease. *Hepatology*, **2019**, 69, 699-716	11.2	21
89	Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?. *Journal of Hepatology* , **2018**, 69, 1371-1383	13.4	21
88	Effects of Endotoxin on Type 3 Inositol 1,4,5-Trisphosphate Receptor in Human Cholangiocytes. *Hepatology*, **2019**, 69, 817-830	11.2	20
87	TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms. *Gut*, **2021**, 70, 1345-1361	19.2	20
86	Oral methylthioadenosine administration attenuates fibrosis and chronic liver disease progression in Mdr2-/- mice. *PLoS ONE*, **2010**, 5, e15690	3.7	18
85	Activation of the developmental pathway neurogenin-3/microRNA-7a regulates cholangiocyte proliferation in response to injury. *Hepatology*, **2014**, 60, 1324-35	11.2	17
84	MicroRNAs in cholangiopathies: Potential diagnostic and therapeutic tools. *Clinics and Research in Hepatology and Gastroenterology*, **2016**, 40, 15-27	2.4	16
83	The significance of genetics for cholangiocarcinoma development. *Annals of Translational Medicine*, **2013**, 1, 28	3.2	16
82	Pathogenesis of Cholangiocarcinoma. *Annual Review of Pathology: Mechanisms of Disease*, **2021**, 16, 433-463	34	16
81	Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach. *Cancers*, **2020**, 12,	6.6	15
80	Novel equation to determine the hepatic triglyceride concentration in humans by MRI: diagnosis and monitoring of NAFLD in obese patients before and after bariatric surgery. *BMC Medicine*, **2014**, 12, 137	11.4	15
79	Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat. *Hepatology*, **2010**, 52, 667-77	11.2	15
78	Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part II: Treatment. *Digestive and Liver Disease*, **2020**, 52, 1430-1442	3.3	15
77	Extracellular Vesicles in Hepatobiliary Malignancies. *Frontiers in Immunology*, **2018**, 9, 2270	8.4	15
76	Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. *Journal of Clinical Investigation*, **2021**, 131,	15.9	15
75	Genetics of polycystic liver diseases. *Current Opinion in Gastroenterology*, **2019**, 35, 65-72	3	14

74	Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma. *American Journal of Pathology*, **2019**, 189, 2090-2101	5.8	14
73	Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression. *American Journal of Pathology*, **2014**, 184, 110-21	5.8	14
72	Novel lncRNA T-UCR as a potential downstream driver of the Wnt/Ecatenin pathway in hepatobiliary carcinogenesis. *Gut*, **2017**, 66, 1177-1178	19.2	13
71	Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. *Hepatology*, **2021**, 73, 2311-2325	11.2	13
70	RIPK1 and death receptor signaling drive biliary damage and early liver tumorigenesis in mice with chronic hepatobiliary injury. *Cell Death and Differentiation*, **2019**, 26, 2710-2726	12.7	11
69	A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma. *Cancers*, **2020**, 12,	6.6	11
68	MRP3-Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression. *Hepatology*, **2020**, 72, 949-964	11.2	11
67	Severity in polycystic liver disease is associated with aetiology and female gender: Results of the International PLD Registry. *Liver International*, **2019**, 39, 575-582	7.9	11
66	Genetics: Novel causative genes for polycystic liver disease. *Nature Reviews Gastroenterology and Hepatology*, **2017**, 14, 391-392	24.2	10
65	Nuclear Translocation of RELB Is Increased in Diseased Human Liver and Promotes Ductular Reaction and Biliary Fibrosis in Mice. *Gastroenterology*, **2019**, 156, 1190-1205.e14	13.3	10
64	Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer differentiation. *Liver International*, **2020**, 40, 3103-3116	7.9	10
63	Measurement of liver iron concentration by MRI is reproducible. *BioMed Research International*, **2015**, 2015, 294024	3	10
62	Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.. *Journal of Hepatology*, **2021**,	13.4	10
61	RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease. *Gut*, **2021**, 70, 2359-2372	19.2	10
60	Extracellular Vesicles in Liver Diseases: Meeting Report from the International Liver Congress 2018. *Hepatology Communications*, **2019**, 3, 305-315	6	10
59	Effect of pravastatin on the survival of patients with advanced gastric cancer. *Oncotarget*, **2016**, 7, 4379-84	5.5	9
58	Functional crosstalk between the adenosine transporter CNT3 and purinergic receptors in the biliary epithelia. *Journal of Hepatology*, **2014**, 61, 1337-43	13.4	9
57	Somatic second-hit mutations leads to polycystic liver diseases. *World Journal of Gastroenterology*, **2013**, 19, 141-3	5.6	9

56	Neutrophils interact with cholangiocytes to cause cholestatic changes in alcoholic hepatitis. *Gut*, **2021**, 70, 342-356	19.2	9
55	miRNA profiling of biliary intraepithelial neoplasia reveals stepwise tumorigenesis in distal cholangiocarcinoma via the miR-451a/ATF2 axis. *Journal of Pathology*, **2020**, 252, 239-251	9.4	9
54	Aging-Related Expression of Twinfilin-1 Regulates Cholangiocyte Biological Response to Injury. *Hepatology*, **2019**, 70, 883-898	11.2	8
53	CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cells. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2019**, 1865, 2246-2256	6.9	7
52	Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets. *Liver International*, **2020**, 40, 1670-1685	7.9	7
51	Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial). *Cancers*, **2020**, 12,	6.6	7
50	Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD. *Frontiers in Medicine*, **2021**, 8, 683250	4.9	7
49	High fluorescence cell count in ascitic body fluids for carcinomatosis screening. *Clinical Chemistry and Laboratory Medicine*, **2018**, 56, 272-274	5.9	6
48	Extracellular Signal-Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells. *Hepatology*, **2021**, 74, 2007-2020	11.2	6
47	Zinc Finger E-Box Binding Homeobox 1 Promotes Cholangiocarcinoma Progression Through Tumor Dedifferentiation and Tumor-Stroma Paracrine Signaling. *Hepatology*, **2021**, 74, 3194-3212	11.2	6
46	Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment. *Digestive Diseases*, **2017**, 35, 275-281	3.2	5
45	Melatonin Protects Cholangiocytes from Oxidative Stress-Induced Proapoptotic and Proinflammatory Stimuli via miR-132 and miR-34. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	5
44	Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models. *Cancer Cell International*, **2012**, 12, 5	6.4	5
43	Zolmitriptan: a novel portal hypotensive agent which synergizes with propranolol in lowering portal pressure. *PLoS ONE*, **2013**, 8, e52683	3.7	5
42	Development of new assays and improved procedures for the purification of recombinant human chymase. *FEBS Journal*, **2001**, 268, 5885-93		5
41	Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality **2021**,		5
40	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. *Liver International*, **2021**, 41, 2076-2086	7.9	5
39	Epigenomic Evaluation of Cholangiocyte Transforming Growth Factor-β Signaling Identifies a Selective Role for Histone 3 Lysine 9 Acetylation in Biliary Fibrosis. *Gastroenterology*, **2021**, 160, 889-905.e10	13.3	5

38	Optimizing the use of twitter for research dissemination: The "Three Facts and a Story" randomized-controlled trial. *Journal of Hepatology*, **2021**, 75, 271-274	13.4	5
37	New Advances in the Molecular Mechanisms Driving Biliary Fibrosis and Emerging Molecular Targets. *Current Drug Targets*, **2017**, 18, 908-920	3	4
36	Molecular Mechanisms of Cholangiocarcinogenesis: New Potential Targets for Therapy. *Current Drug Targets*, **2017**, 18, 932-949	3	4
35	The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma. *EBioMedicine*, **2021**, 73, 103661	8.8	4
34	Multi-Omics Integration Highlights the Role of Ubiquitination in CCl-Induced Liver Fibrosis. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	4
33	Usefulness of serum metabolic profiling in the search of novel diagnostic biomarkers for primary sclerosing cholangitis, intrahepatic cholangiocarcinoma and hepatocellular carcinoma. *Journal of Hepatology*, **2018**, 68, S72-S73	13.4	4
32	rs641738C>T near MBOAT7 is positively associated with liver fat, ALT, and histological severity of NAFLD: a meta-analysis		3
31	Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma. *Hepatology*, **2021**, 73, 2380-2396	11.2	3
30	Novel GANAB variants associated with polycystic liver disease. *Orphanet Journal of Rare Diseases*, **2020**, 15, 302	4.2	3
29	Next-Generation Biomarkers for Cholangiocarcinoma. *Cancers*, **2021**, 13,	6.6	3
28	Long Non-Coding RNA ACTA2-AS1 Promotes Ductular Reaction by Interacting with the p300/ELK1 Complex.. *Journal of Hepatology*, **2021**,	13.4	3
27	Adaptive downregulation of Cl-/HCO3- exchange activity in rat hepatocytes under experimental obstructive cholestasis. *PLoS ONE*, **2019**, 14, e0212215	3.7	2
26	Primers on molecular pathways - ion channels: key regulators of pancreatic physiology. *Pancreatology*, **2009**, 9, 556-9	3.8	2
25	Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. *Cell Death and Disease*, **2021**, 12, 555	9.8	2
24	Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models. *Journal of Hepatology*, **2021**, 74, 394-406	13.4	2
23	Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. *Expert Opinion on Investigational Drugs*, **2021**, 30, 377-388	5.9	2
22	FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. *Journal of Hepatology*, **2021**, 75, 363-376	13.4	2
21	YAP Accelerates Notch-Driven Cholangiocarcinogenesis via mTORC1 in Mice. *American Journal of Pathology*, **2021**, 191, 1651-1667	5.8	2

20	Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. *Molecular Metabolism*, **2021**, 53, 101275	8.8	2
19	Methionine adenosyltransferase 1a antisense oligonucleotides activate the liver-brown adipose tissue axis preventing obesity and associated hepatosteatosis.. *Nature Communications*, **2022**, 13, 1096	17.4	2
18	DHEA Protects Human Cholangiocytes and Hepatocytes against Apoptosis and Oxidative Stress.. *Cells*, **2022**, 11,	7.9	2
17	Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry. *Cancers*, **2022**, 14, 2389	6.6	2
16	Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. *Cancers*, **2020**, 12,	6.6	1
15	MicroRNAs in Liver Diseases **2013**, 509-522		1
14	p-STAT3 is a PDC-E2 interacting partner in human cholangiocytes and hepatocytes with potential pathobiological implications. *Scientific Reports*, **2021**, 11, 21649	4.9	1
13	Applications of organoids in regenerative medicine: a proof-of-concept for biliary injury. *Nature Reviews Gastroenterology and Hepatology*, **2021**, 18, 371-372	24.2	1
12	Inhibition of NAE-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease. *United European Gastroenterology Journal*, **2021**, 9, 848	5.3	1
11	Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease. *Hepatology*, **2021**, 73, 186-203	11.2	1
10	Primary biliary cholangitis: pathogenic mechanisms. *Current Opinion in Gastroenterology*, **2021**, 37, 91-983		1
9	REPLY. *Hepatology*, **2021**, 74, 1129-1131	11.2	1
8	Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?. *Liver Cancer*, **2021**, 10, 545-560	9.1	1
7	REPLY. *Hepatology*, **2021**, 74, 2319-2321	11.2	0
6	Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-□vis anti-SARS-CoV-2 antibodies from a high incidence region. *International Journal of Infectious Diseases*, **2021**, 110, 114-122	10.5	0
5	Reply to: "Diagnostic and prognostic role of circulating microparticles in hepatocellular carcinoma". *Journal of Hepatology*, **2017**,	13.4	
4	Extracellular Vesicles in Non-alcoholic Fatty Liver Disease: Key Players in Disease Pathogenesis and Promising Biomarker Tools **2020**, 157-180		
3	Fibrocystic Diseases of the Liver **2018**, 995-1014.e6		

2	Integrative Proposal for the Use of Biomarkers in Clinical Practice Management of NAFLD/NASH **2020**, 225-236	
1	Reply to: "We need to talk about #livertwitter". *Journal of Hepatology*, **2021**, 75, 1240-1241	13.4